A Study of Tucatinib vs. Placebo in Combination With Trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Condition: HER2-positive Breast Cancer Interventions: Drug: tucatinib; Drug: placebo; Drug: T-DM1 Sponsor: Seattle Genetics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | HER2 | Herceptin | Research | Study